INTRODUCTION AND OBJECTIVES: The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is to evaluate metabolic syndrome in men with PCa undergoing intermittent ADT.
INTRODUCTION AND OBJECTIVES: The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is to evaluate metabolic syndrome in men with PCa undergoing intermittent ADT.
METHODS: In this longitudinal study, we studied the prevalence of metabolic syndrome and its components in 190 patients who were undergoing intermittent ADT. The metabolic syndrome was defined according to the Adult Treatment Panel III criteria. All metabolic parameters, including lipid profile, blood glucose, blood pressures, and waist circumferences of the patients were measured six and 12 months after treatment.
RESULTS: Mean age of the patients was 67.5 AE 6.74 years. The incidence of metabolic syndrome after six and 12 months was 6.8% and 14.7%, respectively. Analysis of various components of the metabolic syndrome revealed that patients had significantly higher overall prevalence of hyperglycemia, abdominal obesity, and hypertriglyceridemia in their six-and 12-month follow ups, but blood pressure has not been changed in the same period except for diastolic blood pressure after six months.
CONCLUSIONS: Although there was an increased risk of metabolic syndrome in patients receiving intermittent ADT, it was lower than other studies that treated the same patients with continuous ADT. Also it seems that intermittent ADT has less metabolic complications than continuous ADT and could be used as a safe alternative in patients with advanced and metastatic PCa.
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MP57-17 POLYMER DELIVERED, SUBCUTANEOUSLY ADMINISTERED LEUPROLIDE ACETATE PROVIDES STABLE AND LONG-TERM DRUG DELIVERY AND TESTOSTERONE SUPPRESSION ACROSS 4 PIVOTAL TRIALS
Franklin Chu*, San Bernardino, CA; John McLane, Fort Collins, CO; Stuart Atkinson, Debbie Boldt-Houle, Lincolnshire, IL; Christopher Pieczonka, Syracuse, NY INTRODUCTION AND OBJECTIVES: Prostate cancer patients receive androgen deprivation therapy (ADT) to suppress testosterone (T) to prevent proliferation of cancer cells. T suppression levels achieved by bilateral orchiectomy remain the gold standard for the target of suppression by ADT. Although the historical threshold definition of castration is T 50 ng/dL, increasing evidence suggests a T lower than 20 ng/dL may improve clinical outcomes, e.g., increased cancer specific survival and delayed disease progression. However, it has not been established what level of serum LA is required to achieve T suppression below this more rigorous threshold. To determine the level of serum leuprolide required to maintain level T suppression 20 ng/dL in prostate cancer patients, data from 4 pivotal trials evaluating long-acting, subcutaneously (SC) administered leuprolide acetate (LA) formulated with a biodegradable polymer were pooled.
METHODS: 438 eugonadal prostate cancer patients (age 40-86) were treated with SC-LA 7.5, 22.5, 30, or 45mg delivered with a single dose lasting over 1, 3, 4, or 6 months (n¼120, 117, 90, 111) , respectively in 4 open-label, fixed-dose, pivotal trials. Descriptive statistics were used to summarize the median concentration of leuprolide acetate at each time point as well as to determine level of T suppression.
RESULTS: Over the dosing intervals of the 1, 3, 4 and 6-month SC-LA formulations, median serum leuprolide levels were consistent. In the pooled analysis (n¼66 with PK assessments), 60(91%) patients with LA !0.1 ng/mL achieved T 20 ng/dL by week 5. Of all patients (n¼438), 90-96% achieved T 20 ng/dL by week 6 and 90-97% maintained T 20 ng/dL from weeks 6-24.
CONCLUSIONS: These data suggest that SC-LA achieves consistent and prolonged drug delivery and that serum LA levels above 0.1 ng/mL provide favorable T suppression below 20 ng/dL. Consistent achievement of these levels may have implications for improved clinical outcomes, e.g., increased cancer specific and progression free survival. METHODS: We developed three classifiers aimed at predicting 1) high-grade disease on final pathology (primary Gleason grade 4/5) and 2) AP (seminal vesicle or bladder neck invasion or lymph node positive disease). For the development of the Grade Group (GG) classifier, we performed genome-wide differential expression analysis between high-(primary pattern 4/5) and low-(primary pattern 3) Gleason grade disease on 967 high-risk prostate cancer (PCa) patients from the Decipher genomic resource information database (GRIDâ, NCT02609269). For the development of the high-grade disease 1 (HGD) classifier, we used differential expression analysis comparing high (!7) and low ( 4) CAPRA-S scores in a retrospective cohort of 425 high-risk RP patients treated at Mayo Clinic and for HGD 2 classifier, we compared patients with a Decipher score !0.7 and Gleason score !8 to those with lowerrisk scores ina prospective cohort of 1817 high-risk RP patients available in GRID. The GG classifier was trained using a deep neural network model with 3 hidden layers consisting of 79 genes using the 00 h2o 00 package in R v3.1. The HGD 1 and HGD 2 classifiers were based on an elastic net algorithm consisting of109 and60 genes, respectively. Two validation cohorts were used: 1) 6,739 Decipher RP profiles (not used in training) in the GRID ordered by 285 centers over 2015-2016 and 2) a retrospective biopsy (Bx) cohort consisting of 107 Decipher biopsy profiles from 4 academic institutions. Discrimination performance of the classifiers was evaluated via the c-index and logistic regression.
RESULTS: On the RP validation cohort, the GG, HGD 1 and HGD 2 classifiers had c-indices of 0.65 (95% confidence interval [CI] 0.64-0.67), 0.67 (95% CI 0.65-0.69) and 0.69 (95% CI 0.67-0.70) for prediction of the AP endpoint, respectively. On the Bx cohort, the GG, HGD 1 and HGD 2 classifiers had c-indices of 0.80 (95% CI 0.70-0.90), 0.82 (95% CI 0.71-0.93) and 0.84 (95% CI 0.74-0.93), respectively, for the prediction of AP after surgery.
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